Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Accumulated Expenses (2020 - 2026)

RxSight filings provide 6 years of Accumulated Expenses readings, the most recent being $19.8 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 2.77% to $19.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.8 million, a 2.77% decrease, with the full-year FY2025 number at $19.8 million, down 2.77% from a year prior.
  • Accumulated Expenses hit $19.8 million in Q4 2025 for RxSight, up from $17.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.4 million in Q4 2024 to a low of $4.8 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $12.7 million (2022), compared with a mean of $12.4 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 88.28% in 2021 and later dropped 2.77% in 2025.
  • RxSight's Accumulated Expenses stood at $7.9 million in 2021, then surged by 61.24% to $12.7 million in 2022, then rose by 20.26% to $15.2 million in 2023, then surged by 33.59% to $20.4 million in 2024, then decreased by 2.77% to $19.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $19.8 million (Q4 2025), $17.6 million (Q3 2025), and $15.9 million (Q2 2025) per Business Quant data.